Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5423586> ?p ?o }
Showing triples 1 to 43 of
43
with 100 triples per page.
- Q5423586 subject Q8256511.
- Q5423586 abstract "F-15,063 is an orally active potential antipsychotic, and an antagonist at the D2/D3 receptors, partial agonist at the D4 receptor, and agonist at the 5-HT1A receptors. It has greater efficacy at the 5-HT1A receptors than other antipsychotics, such as clozapine, aripiprazole, and ziprasidone. This greater efficacy may lead to enhanced antipsychotic properties, as antipsychotics that lack 5-HT1A affinity are associated with increased risk of extrapyramidal symptoms, and lack of activity against the negative symptoms of schizophrenia.As expression of immediate-early gene (IEG) in certain brain regions may represent markers of anti-psychotic activity, expression of immediate-early gene mRNA in the prefrontal cortex and striatum was measured. Treatment with F-15,063 resulted in induction of c-fos and fosB mRNA expression in the prefrontal cortex. In the striatum, F-15,063 treatment resulted in induction of all IEGs studied (c-fos, fosB, zif268, c-jun, junB, nor1, nur77, arc).F-15,063 was tested in several animal models that predict antipsychotic activity to help determine the behavioral profile. Administration of F-15,063 blocked amphetamine and ketamine induced hyperlocomotion, but did not affect baseline, spontaneous locomotor activity. In addition, F-15,063 did not produce catalepsy, a side effect of other antipsychotics, such as haloperidol. This inhibition of catalepsy is 5-HT1A receptor mediated, as pretreatment with the 5-HT1A antagonist WAY-100635 reinstated catalepsy. The level of catalepsy did not increase with chronic dosing, and there was no evidence for serotonin syndrome at clinically relevant doses.Plasma levels of F-15,063 decreased seven-fold 4 hours after oral administration, and 25-fold after 8 hours. Despite this, there was still a high (65%) level of central D2 occupancy at 4 hours, and it retained its full antipsychotic potential at this time point. Even after 8 hours, F-15,063 still demonstrated some central D2 occupancy, and retained some antipsychotic activity.".
- Q5423586 iupacName "(N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine)".
- Q5423586 thumbnail F_15_063.svg?width=300.
- Q5423586 wikiPageWikiLink Q1319792.
- Q5423586 wikiPageWikiLink Q1385411.
- Q5423586 wikiPageWikiLink Q14864821.
- Q5423586 wikiPageWikiLink Q14866071.
- Q5423586 wikiPageWikiLink Q14906123.
- Q5423586 wikiPageWikiLink Q14911907.
- Q5423586 wikiPageWikiLink Q15312073.
- Q5423586 wikiPageWikiLink Q15312389.
- Q5423586 wikiPageWikiLink Q15335165.
- Q5423586 wikiPageWikiLink Q17929096.
- Q5423586 wikiPageWikiLink Q179452.
- Q5423586 wikiPageWikiLink Q18022891.
- Q5423586 wikiPageWikiLink Q18028096.
- Q5423586 wikiPageWikiLink Q18037024.
- Q5423586 wikiPageWikiLink Q18680.
- Q5423586 wikiPageWikiLink Q188928.
- Q5423586 wikiPageWikiLink Q205517.
- Q5423586 wikiPageWikiLink Q208144.
- Q5423586 wikiPageWikiLink Q221361.
- Q5423586 wikiPageWikiLink Q238509.
- Q5423586 wikiPageWikiLink Q243547.
- Q5423586 wikiPageWikiLink Q245204.
- Q5423586 wikiPageWikiLink Q251347.
- Q5423586 wikiPageWikiLink Q409638.
- Q5423586 wikiPageWikiLink Q41112.
- Q5423586 wikiPageWikiLink Q411188.
- Q5423586 wikiPageWikiLink Q616181.
- Q5423586 wikiPageWikiLink Q770260.
- Q5423586 wikiPageWikiLink Q7946879.
- Q5423586 wikiPageWikiLink Q8256511.
- Q5423586 wikiPageWikiLink Q918193.
- Q5423586 type ChemicalCompound.
- Q5423586 type ChemicalSubstance.
- Q5423586 type ChemicalObject.
- Q5423586 type Thing.
- Q5423586 type Q11173.
- Q5423586 comment "F-15,063 is an orally active potential antipsychotic, and an antagonist at the D2/D3 receptors, partial agonist at the D4 receptor, and agonist at the 5-HT1A receptors. It has greater efficacy at the 5-HT1A receptors than other antipsychotics, such as clozapine, aripiprazole, and ziprasidone.".
- Q5423586 label "F-15063".
- Q5423586 depiction F_15_063.svg.